Abstract

The MarketScan Commercial Database (previously called the 'MarketScan Database') contains real-world data for healthcare research and analytics to examine health economics and treatment outcomes.

This page also contains the MarketScan Commercial Lab Database starting in 2018.

Methodology

MarketScan Research Databases are a family of data sets that fully integrate many types of data for healthcare research, including:

• De-identified records of more than 188 million patients (medical, drug and dental)

%3C!-- --%3E

• Laboratory results

%3C!-- --%3E

• Hospital discharges

%3C!-- --%3E

The MarketScan Databases track millions of patients throughout the healthcare system. The data are contributed by large employers, managed care organizations, hospitals, EMR providers, and Medicare.

Usage

This page contains the MarketScan Commercial Database.

We also have the following on other pages:

• The MarketScan Medicare Supplemental Database
• The MarketScan Dental Database
• The MarketScan Benefit Plan Design data
• MarketScan Redbook (The MarketScan Code Reference Book)

%3C!-- --%3E

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

Section 2

Metadata access is required to view this section.

Section 3

Metadata access is required to view this section.

Usage FAQs (Answers provided in User Guide starting on page 56)

Metadata access is required to view this section.

Abstract

The MarketScan Medicare Supplemental Database provides detailed cost, use and outcomes data for healthcare services performed in both inpatient and outpatient settings.

It Include Medicare Supplemental records for all years, and Medicare Advantage records starting in 2020.

This page also contains the MarketScan Medicare Lab Database starting in 2018.

Methodology

MarketScan Research Databases are a family of data sets that fully integrate many types of data for healthcare research, including:

• De-identified records of more than 250 million patients (medical, drug and dental)

%3C!-- --%3E

• Laboratory results

%3C!-- --%3E

• Hospital discharges

%3C!-- --%3E

The MarketScan Databases track millions of patients throughout the healthcare system. The data are contributed by large employers, managed care organizations, hospitals, EMR providers and Medicare.

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

Section 2

Metadata access is required to view this section.

Section 3

Metadata access is required to view this section.

Abstract

The MarketScan Dental Database is a standalone product that corresponds with and is linkable to a given year and version of the IBM MarketScan Commercial Claims and Encounters Database and the MarketScan Medicare Supplemental and Coordination of Benefits Database. Currently, data is available for the years: 2005 - 2023. In order to view the MarketScan Dental user guide or data dictionary, you must have data access to this dataset.

Usage

In addition to what's on this page, we also have:

• The MarketScan Commercial Database
• The MarketScan Medicare Supplemental Database
• The MarketScan Benefit Plan Design data

%3C!-- --%3E

• MarketScan Redbook (The MarketScan Code Reference Book)

%3C!-- --%3E

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

Section 3

Metadata access is required to view this section.

Section 4

Metadata access is required to view this section.

Section 5

Metadata access is required to view this section.

Section 6

Metadata access is required to view this section.

Software suite of proprietary databases that contain one of longest running and largest collection of privately and publicly insured, de identified patient data in USA. Family of data sets that fully integrate many types of data for healthcare research.

Abstract

Lookup table (Code Reference Book) for MarketScan

Usage

Redbook is cumulative, so the most recent Redbook can be used for all years.

In addition to what's on this page, we also have:

• The MarketScan Commercial Database

%3C!-- --%3E

• The MarketScan Medicare Supplemental Database
• The MarketScan Dental Database
• The MarketScan Benefit Plan Design data

%3C!-- --%3E

Before Manuscript Submissions

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

This dataset is a de-identified summary table of prevalence rates for vision and eye health data indicators from the 2016 MarketScan® Commercial Claims and Encounters Data (CCAE) is produced by Truven Health Analytics, a division of IBM Watson Health. The CCEA data contain a convenience sample of insurance claims information from person with employer-sponsored insurance and their dependents, including 43.6 million person years of data. Prevalence estimates are stratified by all available combinations of age group, gender, and state. Detailed information on VEHSS MarketScan analyses can be found on the VEHSS MarketScan webpage (cdc.gov/visionhealth/vehss/data/claims/marketscan.html). Information on available Medicare claims data can be found on the IBM MarketScan website (https://marketscan.truvenhealth.com). The VEHSS MarketScan summary dataset was last updated November 2019.

Abstract

We had to delete V3 of MarketScan because of some unusual circumstances with the formats of some of the files we were sent (to prevent the duplication of records). V3.1 contains all of the info that was in V3, however V3.1 has 2022 data & a slightly different version of the 2021 data. The data on this page is the version of the 2021 data that was in V3. Our purpose in posting this is to enable researchers who completed analyses on V3 to replicate their work by combining the data here with the data on the main page.

FOR THE MAJORITY OF RESEARCHERS, however, we strongly recommend using V3.1, and ignoring this page, as it will be irrelevant for most research going forward. (Rule of thumb: If you are unsure whether you need the data on this page, then you probably don't need it.)

Usage

To recreate V3 of the data, use the data for 2020 and earlier that is on the main MarketScan Databases page, and combine it with the data on this page. That will give you the *exact *same data that was in V3.

The data documentation on the main MarketScan page also applies to the data on this page.

How is the data on this page different from the 2021 data on the main MarketScan page?

Metadata access is required to view this section.

Characteristics of infants with an acute MA RSV LRTI during their first RSV season, by insurance claims database and index diagnosis definition.

Abstract

The MarketScan Benefit Plan Design Database represents the benefit plans for large employers whose claims data comprise portions of the MarketScan Commercial Claims and Encounters Database. Currently, data is available for 2013 - 2023.

Usage

In addition to what's on this page, we also have:

• The MarketScan Commercial Database
• The MarketScan Medicare Supplemental Database
• The MarketScan Dental Database

%3C!-- --%3E

• MarketScan Redbook (The MarketScan Code Reference Book)

%3C!-- --%3E

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Documentation

Data access is required to view this section.

Study sample baseline characteristics at index admission for Clostridium difficile compared with all Truven hospital admission claims in 2011.

Crude and age–standardized pregnancy rates per 1,000 person-year of females aged 13–19 years, overall and according to mental disorder type.

The potential therapeutic benefit of fluoxetine with standard of care treatment was evaluated in GBM patients cohort using electronic medical records from the IBM MarketScan Dataset (2003-2017). GBM Patients with two other SSRIs, citalopram and escitalopram, were used as controls. The dataset includes six figures: data S1 Figures 1-6 which provide more details of the data overview, data extraction pipeline, exclusion criteria, enrichment for GBM patients, statistical analyses, and results.

Risk estimates of gastrointestinal (GI) diagnoses after an index case of Clostridium difficile.

The table Outpatient Claims is part of the dataset V3 2021 Files: MarketScan Database, available at https://stanford.redivis.com/datasets/1yk5-4br9tf5nj. It contains 439430636 rows across 58 variables.

Abstract

We had to delete V3 of MarketScan Medicare Supplemental because of some unusual circumstances with the formats of some of the files we were sent (to prevent the duplication of records). V3.1 contains all of the info that was in V3, however V3.1 has 2022 data & a slightly different version of the 2021 data. The data on this page is the version of the 2021 data that was in V3. Our purpose in posting this is to enable researchers who completed analyses on V3 to replicate their work by combining the data here with the data on the main page.

FOR THE MAJORITY OF RESEARCHERS, however, we strongly recommend using V3.1, and ignoring this page, as it will be irrelevant for most research going forward. (Rule of thumb: If you are unsure whether you need the data on this page, then you probably don't need it.)

Usage

To recreate V3 of the data, use the data for 2020 and earlier that is on the main MarketScan Medicare Supplemental page, and combine it with the data on this page. That will give you the exact same data that was in V3.

The data documentation on the main MarketScan Medicare Supplemental page also applies to the data on this page.

How is the data on this page different from the 2021 data on the main MarketScan Medicare Supplemental page?

Metadata access is required to view this section.

These are peer-reviewed supplementary materials for the article 'Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Mean (SD) number of inpatient admissions per patient in individuals with SMA in the 12 months before and after nusinersen treatment. Mean (SD) number of days spent in hospital per patient in individuals with SMA in the 12 months before and after nusinersen treatment.Supplementary Figure 2: Mean (SD) ED visits and costs per patient in individuals with SMA in the 12 months before and after nusinersen treatment.Supplementary Table 1: Patient baseline characteristics of cohorts aligned with steps of patient selection criteria (who were ultimately excluded) in comparison to final cohort.Aim: Nusinersen, administered by intrathecal injection at a dose of 12 mg, is indicated across all ages for the treatment of spinal muscular atrophy (SMA). Evidence on real-world healthcare resource use (HRU) and costs among patients taking nusinersen remains limited. This study aimed to evaluate real-world HRU and costs associated with nusinersen use through US claims databases. Patients & methods: Using the Merative™ MarketScan R ? Research Databases, patients with SMA receiving nusinersen were identified from commercial (January 2017 to June 2020) and Medicaid claims (January 2017 to December 2019). Those likely to have complete information on the date of nusinersen initiation and continuous enrollment 12 months pre- and post-index (first record of nusinersen treatment) were retained. Number and costs (US$ 2020) of inpatient admissions and emergency department (ED) visits, unrelated to nusinersen administration, were evaluated for 12 months pre- and post-nusinersen initiation and stratified by age: pediatric (

The table Prescription Drug Claims is part of the dataset V3 2021 Files: MarketScan Medicare Supplemental Database, available at https://stanford.redivis.com/datasets/3bqx-13fserq78. It contains 28469352 rows across 53 variables.

Data are number or percent (95% CI). p-Value is for the difference between the two groups.Annual frequency of asthma-related emergency room visits and asthma-related hospitalizations: comparing adenotonsillectomy to no adenotonsillectomy.

This table provides the data for age and gender comparisons of the three different treatment modalities for keloid management using the Truven Marketscan Insurance claims database. The average treatment length and average number of visits are reported with their respective median and 25th and 75th percentiles.

The table Enrollment Detail is part of the dataset V3 2021 Files: MarketScan Database, available at https://stanford.redivis.com/datasets/1yk5-4br9tf5nj. It contains 188308277 rows across 26 variables.